Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity therapy, and amylin analogs, some of which have already passed phase 3 clinical trials, are now among the most promising approaches in overweight and obesity pharmacotherapy.
Autoren
- Dr. Stephanie Niklaus
- Prof. Dr. med. vet. Thomas A. Lutz
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Amyotrophic lateral sclerosis and nutrition
Calorie optimization in ALS through digital intervention
- "Forgotten axis" between plant substances, gut and systemic health
Microbiome and phytotherapy
- HIV: updated EACS guideline
Individualized approach to sustainable prevention and care
- Evidence-based diagnostics and treatment in the medical setting
Anxiety and depression disorders in adolescence
- Neuroenhancement
Can you swallow intelligence? Relevant substance classes times for healthy people
- Microbiome, inflammaging and affective/cognitive health
Gut-brain axis in old age
- Vitiligo - the level of suffering should not be underestimated
A lot can be achieved therapeutically nowadays
- Vector-borne infections with skin manifestations